Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction,
remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary …

Pulmonary arterial hypertension (PAH) is a complex disease that causes significant
morbidity and mortality and is clinically characterized by an increase in pulmonary vascular …

Recent investigations have suggested that it might be possible to reverse the pathology of
pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal …

The pathogenesis of pulmonary arterial hypertension (PAH) involves a complex and
multifactorial process in which endothelial cell dysfunction appears to play an integral role in …

Pulmonary arterial hypertension (PAH) is a disorder in which mechanical obstruction of the
pulmonary vascular bed is largely responsible for the rise in mean pulmonary arterial …

Pulmonary artery vasoconstriction and vascular remodeling greatly contribute to a sustained
elevation of pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) in …

Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial
obstruction increases pulmonary vascular resistance, which leads to right ventricular (RV) …

Our understanding of, and approach to, pulmonary arterial hypertension has undergone a
paradigm shift in the past decade. Once a condition thought to be dominated by increased …

Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the
pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of …

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease with a relentless
course toward heart failure and early death. Existing PAH therapies, all of which were …